Ovarian cancer treatment on fast track for FDA approval as chemo alternatives emerge: 'We're making progress'

Ovarian cancer drug RC88 by RemeGen received FDA approval for Phase 2 clinical trials. Gynecologic oncologist Dr. Brian Slomovitz and other experts weigh in on the drug's potential.

As ovarian cancer develops, the level of mesothelia increases — which gives RC88 its "unique" target.  Angelica Stabile is a lifestyle writer for Fox News Digital.

The drug received fast-track designation (FTD) for the treatment of "platinum-resistant recurrent epithelial ovarian, fallopian tube and primary peritoneal cancers," the company confirmed to Fox News Digital.